Company intelligence / Profile preview

Sinopep-Allsino Biopharmaceutical

Lianyungang, Jiangsu, Chinasinopep.com ↗

Ownership: Private
Employees: ~2000
Development stage: Commercial

Overview

Sinopep-Allsino has a robust pipeline with several synthetic peptide drugs advancing through clinical development. Its lead program—semaglutide—is in Phase 3 trials for obesity. The company also provides APIs of major peptides such as semaglutide and tirzepatide at commercial scale. It operates FDA-inspected facilities and offers end-to-end CRDMO services globally.

Therapeutic areas: OncologyEndocrinologyCardiovascular
Modalities: PeptidesSmall moleculeOligonucleotides
Industry: Biotech

Drug pipeline

5 assets

semaglutide

Commercial

Indications: Diabetes

4 more assets in the full pipeline.

Partnerships

Joint venture with Vazyme Biotech announced June 2025multiple global pharma partners via API supply/CDMO business

Beyond the preview

Go deeper on Sinopep-Allsino Biopharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sinopep-Allsino Biopharmaceutical.